Using non-coding small RNAs to develop therapies for Huntington's disease.
about
Mechanisms of RNA-induced toxicity in CAG repeat disordersPluripotent stem cells models for Huntington's disease: prospects and challengesAllele-specific silencing of mutant huntingtin in rodent brain and human stem cellsRepair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic CardiomyopathyEpigenetic mechanisms of neurodegeneration in Huntington's diseaseAblation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.Cell-based therapies for Huntington's disease.Examination of Huntington's disease in a Chinese familyTranscription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspectiveMechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathwayBone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defectsA brief history of triplet repeat diseases.Pre-mRNA splicing in disease and therapeutics.Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?Noncoding RNAs in Neurodegenerative DiseasesCauses and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases.Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs.Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.[Gene silencing approaches for the treatment of Huntington's disease].Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.
P2860
Q26860030-DF714133-F0A1-4853-B41C-4A38B34CE386Q26860151-BCCBB1AA-F77F-460B-9128-8616AF424C88Q27324212-E8F44E63-662C-4DD9-8FE3-65B0ACE4FBC0Q28293833-66E5F195-3ECC-435B-9436-7AB2FA9F6BC7Q28297936-122ABAB0-F19A-47B4-B4D5-1B0215D10C00Q30356472-122BB242-D006-4771-A171-411F28AEA469Q30358344-E95F4929-CEEA-4CB0-8F1F-C5D24932A809Q30385729-EAC5063D-5CF7-4089-9ED6-E10400C755E1Q33849242-499B3C5E-CDD1-47B1-81E0-C6869ACD1709Q34095823-E92179CE-25B0-4275-91AD-BA241A93E079Q35024695-ACFC204B-9AD0-4E37-AE83-4373B72B18D9Q36477988-762F2B78-EDAD-4523-9EFD-063802FFDDC2Q36960987-A481C326-4E49-4263-9523-15226164A37DQ37553564-A17D8411-561E-49F6-A20C-C2DE38765719Q38028093-514DF058-34D2-4FD4-9849-270FCF25F839Q38091009-5B78FFC6-6EF4-4633-98A5-92446CF87C40Q38112127-8CFB8FB7-66DB-4E9F-BD00-D06584C242B2Q38224066-779A8E5F-4C04-43E1-BA38-D045E489AF60Q39256709-205764C4-111F-46B3-A0E9-106CC12ABFDAQ41187089-F4F738BB-B9D7-4442-8E56-9E260397B381Q45304660-054DB840-4897-4B7F-ABBB-C70FDDDA88C8Q46236725-84DAAF06-9C67-4FA1-92CF-D471913A5D16
P2860
Using non-coding small RNAs to develop therapies for Huntington's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Using non-coding small RNAs to develop therapies for Huntington's disease.
@en
Using non-coding small RNAs to develop therapies for Huntington's disease.
@nl
type
label
Using non-coding small RNAs to develop therapies for Huntington's disease.
@en
Using non-coding small RNAs to develop therapies for Huntington's disease.
@nl
prefLabel
Using non-coding small RNAs to develop therapies for Huntington's disease.
@en
Using non-coding small RNAs to develop therapies for Huntington's disease.
@nl
P2860
P356
P1433
P1476
Using non-coding small RNAs to develop therapies for Huntington's disease.
@en
P2093
R M Friedlander
P2860
P2888
P304
P356
10.1038/GT.2011.170
P577
2011-12-01T00:00:00Z